Synthetic Biologics (SYN) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free SYN Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineGenScript Singapore's Open Day Reveals Pioneering AI Capabilities in Recombinant Protein Production and Drug Discoveryfinance.yahoo.com - April 24 at 12:07 AMActive Pharmaceutical Ingredient Market Trends Signal Growth Towards USD 446.6 Billion by 2032 With CAGR AT 6.4%finance.yahoo.com - April 23 at 2:06 PMTheriva Biologics Announces Positive Data From Phase 1 Trial Of VCN-01 In Intraocular Retinoblastomamarkets.businessinsider.com - April 23 at 2:06 PMElon Musk rejects Tucker Carlson’s viral alien conspiracy theorymsn.com - April 22 at 5:48 PMAziyo Biologics Poised for Growth: Buy Rating Affirmed Amidst Anticipated FDA Clearance and Strong Financial Outlookmarkets.businessinsider.com - April 19 at 3:26 PMX-Therma Announces XT-Thrive® Drug Master File (DMF) Accepted by U.S. Food and Drug Administration (FDA)finance.yahoo.com - April 17 at 9:52 AMMustGrow Biologics to Present at the Planet MicroCap Showcasefinance.yahoo.com - April 17 at 9:52 AM31 Netizens Share What They Consider To Be Next Big Changes In The Culture Of The Internetmsn.com - April 10 at 8:07 PMAffini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR ...businesswire.com - April 7 at 11:51 PMSix Arizona Startups Driving Biosciences Forward in 2024finance.yahoo.com - April 3 at 4:13 PMRetinitis Pigmentosa Market to Grow Rapidly at a CAGR of 16.8% by 2034 | DelveInsightfinance.yahoo.com - April 2 at 6:24 PMBCC Research Reveals Top Ten Suppliers of Synthetic Biology Technology in 2024tmcnet.com - April 2 at 1:59 PMPharmaceutical Membrane Filtration Market is Expected to Reach $19.6 billion | MarketsandMarkets™finance.yahoo.com - March 30 at 2:10 AMBuy Recommendation for Theriva Biologics Backed by Promising Oncolytic Adenovirus Platform and Clinical Trial Advancementsmarkets.businessinsider.com - March 27 at 7:41 PMWhy Is Your Pubic Hair Itchy—and How Can You Treat It?msn.com - March 26 at 12:36 PMUpdated recommendations for psoriatic arthritismsn.com - March 25 at 4:34 PMHumacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcriptmsn.com - March 23 at 11:04 AM6 Analysts Assess Absci: What You Need To Knowmarkets.businessinsider.com - March 22 at 5:56 PMSamsung Life Science Fund invests in Massachusetts-based BrickBiomsn.com - March 19 at 9:45 AMWhat Is Pustular Psoriasis?yahoo.com - March 18 at 10:38 AMGRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officerfinance.yahoo.com - March 18 at 8:43 AMSamsung Invests in BrickBio to Develop Advanced Molecules and Therapies Using Protein Engineering Technology for Antibody-Drug Conjugates (ADC)finance.yahoo.com - March 18 at 8:43 AMBlinken Calls for Closer Global Cooperation on Tackling Synthetic Drugsusnews.com - March 17 at 10:42 PMAgricultural Biologicals Market Analysis Report 2024-2030 - Market to Reach USD 12.62 Billion by 2030, Asia-Pacific to Exhibit Rapid Growthfinance.yahoo.com - March 14 at 2:53 PMAfter 50 years, Tommy John surgery is evolving to increase success and sometimes speed returnmsn.com - March 14 at 8:33 AMGenScript Biotech Corporation: GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%finanznachrichten.de - March 12 at 10:37 AMPearl Bio Inks Collaboration with Merck to Discover Novel Engineered Biologicsfinance.yahoo.com - March 12 at 8:34 AMOrthofix Medical Inc. (NASDAQ:OFIX) Q4 2023 Earnings Call Transcriptmsn.com - March 7 at 10:28 AMSurGenTec® Receives FDA Clearance for OsteoFlo® HydroPutty™, a Hydrophilic Synthetic Bone Graftfinance.yahoo.com - March 7 at 10:28 AMThe Analyst Landscape: 4 Takes On Abscimarkets.businessinsider.com - March 6 at 6:09 PM3 AI-Driven Drug Stocks to Buy Before They Breakouttheglobeandmail.com - February 29 at 6:11 PMHow to manage eczema – according to a dermatologistmsn.com - February 29 at 1:11 PMBayer, AgStart launch competition to find ag and food startups that need free lab spacebizjournals.com - February 29 at 1:11 PMbit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Networkfinance.yahoo.com - February 28 at 8:14 AMShort sales on the TSX: What bearish investors are betting againsttheglobeandmail.com - February 26 at 12:13 PMTwist Bioscience (TWST) Price Target Increased by 19.85% to 41.57msn.com - February 25 at 6:10 AMYour Guide To Axial Spondyloarthritis Treatmentsmsn.com - February 23 at 9:35 AMNurExone Biologic Inc: NurExone Launches Licensing Efforts for ExoTherapy Platformfinanznachrichten.de - February 15 at 9:35 AMGroup hits lone Democrat over drug pricing billaxios.com - February 14 at 12:10 AMNebraska lawmakers to hear bill that asks farmers to use biologic products rather than synthetic nitrogenmsn.com - February 14 at 12:10 AMNebraska senator trying to pass bill that would provide farmers with incentives to use biologic products rather than synthetic nitrogenmsn.com - February 14 at 12:10 AMHumacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Traumamsn.com - February 12 at 1:51 PMHumacyte Receives FDA Priority Review for Vascular Repair Solutionmarkets.businessinsider.com - February 10 at 8:12 AMWhy Is Clinical-Stage Biotechnology Platform Company Humacyte Stock Gaining Friday?msn.com - February 9 at 2:33 PMHumacyte gains on FDA priority review for bioengineered blood vesselmsn.com - February 9 at 9:32 AMErectile Dysfunction Drugs Like Viagra May Reduce Alzheimer’s Risk, Study Findsmsn.com - February 8 at 2:15 PMBiosimilar insulin: Startup takes new approach to make insulin affordablemsn.com - February 4 at 5:07 AMRise Therapeutics begins rheumatoid arthritis therapy trialmsn.com - January 30 at 6:00 PMFirst Patient Enrolled in Rise Therapeutics' Rheumatoid Arthritis Clinical Trialfinance.yahoo.com - January 29 at 10:38 AMMerck inks $220M deal for cancer drug discoverymsn.com - January 23 at 3:03 PM Get Synthetic Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter. Email Address The World's First "$20 Trillion Drug?" (Ad)One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%! Get the name of the stock here >>> SYN Media Mentions By Week SYN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYN News Sentiment▼0.350.41▲Average Medical News Sentiment SYN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYN Articles This Week▼53▲SYN Articles Average Week Get Synthetic Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Talphera News Cocrystal Pharma News Kiora Pharmaceuticals News Aytu BioPharma News VBI Vaccines News NeuroBo Pharmaceuticals News Minerva Neurosciences News Benitec Biopharma News Orgenesis News Ceapro News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:SYN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synthetic Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
